ICU Medical (ICUI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
$161.00+0.07%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-09
Intact: The reason to own it still holds.
ICU Medical improved net income to $30.1M in 2026-Q1. Cash from operations rose to $51.3M in 2026-Q1. Competitors have quality problems, helping ICU Medical's market share. Moody's upgraded ICU's rating, supporting cash flow outlook.
Gross profit fell slightly to $206.2M in 2026-Q1. Revenue fell 12% year over year in 2026-Q1. Leadership changes may disrupt integration efforts.
The price is near our fair value of $157. Analysts expect about 3.5% revenue growth. Our fair value is below the Street median by 4%.
Breaks if: cash from operations falls below $51 million in any future quarter
Enhance cash flow generation from operating activities to support financial flexibility.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on improving financial metrics. The current thesis state is intact, supported by strong recent earnings and management's commitment to enhancing profitability.
The market appears to expect continued improvement in ICUI's performance, given its recent strong results. However, the valuation is considered expensive compared to peers, indicating that high expectations are already priced in.
Management is on track to improve net income, cash from operations, and gross profit, which supports a positive fundamental trajectory. Despite a low probability of missing earnings expectations, there is a history of significant misses that could weigh on investor sentiment.
The thesis hinges on maintaining credibility with guidance after recent earnings beats. Additionally, broader sector performance and economic indicators, such as job growth, will significantly impact ICUI's outlook.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports improved net income. Strong organic growth and margin expansion enhance gross profit significantly.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 of last 4 quarters. Net cash provided by operating activities increased from $62.5 million in first half 2025 to $119.1 million in first half 2026. Management is delivering improved cash flow generation consistent with stated goals.
“Net cash provided by operating activities was $119.1 million for the six months ended June 30, 2026.”
“Net cash provided by operating activities was $38.9 million for the three months ended March 31, 2026.”
“Net cash provided by operating activities was $62.5 million for the six months ended June 30, 2025.”
“Management emphasized improving cash flow generation.”
Breaks if: gross profit falls below $206 million in any future quarter
Focus on improving gross profit margins through operational efficiencies and product mix.
Stated as a priority in 4 of last 4 quarters. GAAP gross margin improved from 38% in 2025-Q2 to 43% in 2026-Q2, demonstrating progress in operational efficiencies and product mix. The trajectory shows delivering on gross profit enhancement.
“GAAP gross margin for the second quarter of 2026 was 43%, as compared to 38% in the same period in the prior year.”
“GAAP gross margin for the first quarter of 2026 was 39%, as compared to 35% in the same period in the prior year.”
“GAAP gross margin for the fourth quarter of 2025 was 38%, as compared to 36% in the same period in the prior year.”
“Management focused on gross profit improvement initiatives.”
Breaks if: net income falls below $30 million in any future quarter
Focus on increasing net income through operational improvements and strategic divestitures.
Stated as a priority in 4 of last 4 quarters. GAAP net income improved from a loss of $(15.7) million in 2025-Q4 to a profit of $19.1 million in 2026-Q2, with adjusted diluted EPS rising from $1.91 to $2.37 over the same period. Management's focus on improving net income is delivering a positive trajectory.
“Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.”
“First quarter results were generally in line with our expectations.”
“Fourth quarter results were generally in line with our expectations.”
“CEO emphasized improving profitability and operational performance.”
Breaks if: revenue growth falls below 3.5% year over year next year
Over the next 1 to 3 years, ICUI's performance will depend on its ability to sustain operational improvements and navigate potential economic challenges. Not investment advice.